Orgenesis (NASDAQ:ORGS – Get Free Report) is projected to release its resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($2.60) per share and revenue of $2.80 million for the quarter.
Orgenesis Stock Performance
NASDAQ ORGS opened at $0.05 on Wednesday. Orgenesis has a twelve month low of $0.00 and a twelve month high of $0.91. The stock has a market cap of $241,392.30, a price-to-earnings ratio of -0.00 and a beta of 3.64. The firm’s 50 day moving average price is $0.30 and its two-hundred day moving average price is $0.36.
Orgenesis Company Profile
Orgenesis Inc is a biotechnology company focused on cell and gene therapy development and the technologies needed to manufacture these treatments closer to the point of patient care. Its work combines therapeutic programs with bioprocessing systems intended to support the production of personalized, autologous cell therapies.
The company’s technology platform includes its Point-of-Care (POCare) ecosystem and Mobile Processing Units (MPUs). These systems are designed to provide controlled, modular environments for processing patient-derived cells at hospitals, clinics, and other treatment sites, with the goal of reducing reliance on centralized manufacturing facilities.
Orgenesis has pursued collaborations with academic institutions, healthcare organizations, and biotechnology partners in the United States and internationally.
Featured Articles
- Five stocks we like better than Orgenesis
- High Voltage Returns: Talen Energy Powers the Data Center Rush
- 3 Dividend Increases Above 10%, But Which Offers the Most Income?
- Meta’s $100 Billion AI Financing Plan Has a Catch for Existing Shareholders
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
